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ABSTRACT 
Ferroptosis is an iron-dependent form of necrotic cell death marked by oxidative damage to 
phospholipids1,2. To date, ferroptosis has been believed to be restrained only by the phospholipid 
hydroperoxide (PLOOH)-reducing enzyme glutathione peroxidase 4 (GPX4)3,4 and radical-
trapping antioxidants (RTAs)5,6. The factors which underlie a given cell type’s sensitivity to 
ferroptosis7 is, however, critical to understand the pathophysiological role of ferroptosis and how 
it may be exploited for cancer treatment. Although metabolic constraints8 and phospholipid 
composition9,10 contribute to ferroptosis sensitivity, no cell-autonomous mechanisms have been 
yet been identified that account for ferroptosis resistance. We undertook an expression cloning 
approach to identify genes able to complement GPX4 loss. These efforts uncovered the 
flavoprotein “apoptosis inducing factor mitochondria-associated 2 (AIFM2)” as a previously 
unrecognized anti-ferroptotic gene. AIFM2, hereafter renamed “ferroptosis-suppressor-protein 
1” (FSP1), initially described as a pro-apoptotic gene11, confers an unprecedented protection 
against ferroptosis elicited by GPX4 deletion. We further demonstrate that ferroptosis 
suppression by FSP1 is mediated via ubiquinone (CoQ10): its reduced form ubiquinol traps lipid 
peroxyl radicals that mediate lipid peroxidation, while FSP1 catalyses its regeneration by using 
NAD(P)H. Pharmacological targeting of FSP1 strongly synergizes with GPX4 inhibitors to trigger 
ferroptosis in a number of cancer entities. Conclusively, FSP1/CoQ10/NAD(P)H exists as a stand-
alone parallel system, which co-operates with GPX4 and glutathione (GSH) to suppress 
phospholipid peroxidation (pLPO) and ferroptosis.  
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Results 
Ferroptosis is controlled by the selenoenzyme GPX43,4,12. With the recognition that targeting 
ferroptosis may help eradicate therapy-resistant tumors13-15, there is mounting interest in 
understanding the mechanisms that underpin cell sensitivity to ferroptosis16. Although acyl-CoA 
synthetase long chain family member 4 (ACSL4) was identified as a pro-ferroptotic gene, whose 
expression determines ferroptosis sensitivity9,10, inhibition of GPX4 fails to trigger ferroptosis in 
some cancer cell lines regardless of ACSL4 expression, suggesting alternative resistance 
mechanisms.  
Genetic suppressor screen uncovers FSP1 
To uncover these factors, we generated a cDNA expression library derived from the MCF7 
ferroptosis-resistant cell line9,10 (Extended Data Fig. 1a), and screened for genes complementing 
GPX4 loss (Fig. 1a). Sequencing of 14 single cell clones identified 7 which express both GPX4 and 
AIFM2 (Extended Data Fig. 1b). AIFM2 is a flavoprotein originally described as a p53-responsive 
gene17. It was initially claimed to induce apoptosis based on sequence similarity to another 
initially postulated pro-apoptotic gene, apoptosis-inducing factor, mitochondria-associated, 1 
(AIFM1)11. To avoid further confusion, we thus recommend future reference to AIFM2 be made 
as “Ferroptosis-Suppressor-Protein 1 (FSP1)” (accompanying manuscript Besuker et al.). For 
validation, we stably expressed FSP1 in Pfa118 and in human fibrosarcoma HT1080 cells (Extended 
Data Fig. 1c,d). FSP1 overexpressing cells were robustly protected against pharmacological and 
genetic ferroptosis inducers1 and proliferated indefinitely (Fig. 1b-e; Extended Data Fig. 1e-i; 
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Supplementary information Video). To the best of our knowledge, this is the first enzymatic 
system complementing GPX4 loss18. 
Its anti-ferroptotic function was found to be independent of cellular GSH levels, GPX4 activity, 
ACSL4 expression and oxidizable fatty acid content (Extended Data Fig. 1c,d,j,k; Extended Data 
Fig. 2), showing that FSP1 does not interfere with canonical ferroptosis mechanisms. Moreover, 
the protection conferred by FSP1 was specific to ferroptosis-inducing agents, and not cytotoxic 
compounds and/or pro-apoptotic conditions. Moreover, p53 status did not impact on FSP1 
expression (Extended Data Fig. 3a-e). In contrast to FSP1, overexpression of AIFM1 failed to 
suppress ferroptosis (Extended Data Fig. 3f,g). 
N-myristoylation of FSP1 is essential 
Early efforts revealed that N-terminal tagging of FSP1 abolished its anti-ferroptotic activity. 
Indeed, the N-terminus of FSP1 contains a canonical myristoylation motif19, presumably 
facilitating its association with lipid bilayers20. Expression of wildtype and a mutant form of FSP1 
lacking the predicted myristoylation site [G2A] in Pfa1 and HT1080 cells (Fig. 2a), and tagging with 
an alkyne-functionalized myristic acid mimetic (YnMyr) enabled the specific enrichment of only 
wildtype FSP1. This enrichment was abolished with both the G2A mutation and the pan-N-
myristoyl transferase inhibitor IMP-108821 (Fig. 2b). Myristoylation of FSP1 appears to be 
essential for its anti-ferroptotic role as the G2A mutant and wildtype FSP1 expressing cells treated 
with IMP-1088 abrogated ferroptosis resistance (Fig. 2c,d; Extended Data Fig. 3 h,i). Intrigued by 
these findings, we assessed the subcellular distribution of both the wildtype and G2A mutant 
FSP1 using C-terminally tagged fusion proteins. Although FSP1-GFP localized to an unspecified 
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perinuclear membrane compartment, it also partially overlapped with ER and Golgi markers (Fig. 
2e; Extended Data Fig. 4a). In contrast, FSP1[G2A]-GFP was distributed throughout the cell, 
suggesting that ferroptosis is perhaps driven in a specific subcellular region. A more sophisticated 
investigation of the subcellular localization of FSP1 is provided by Besuker et al., revealing a 
striking role for plasma membrane-targeted FSP1 in ferroptosis suppression. 
FSP1 prevents lipid peroxidation 
Since ferroptosis is ultimately driven by pLPO, we stained Pfa1 cells with C11-BODIPY 581/591 to 
find that FSP1 overexpression blunted lipid peroxidation induced by (1S/3R)-RSL3 (RSL3) (Fig. 3a). 
Moreover, specific pLPO products were markedly lower in Gpx4 knockout (KO) FSP1 
overexpressing cells (Fig. 3b; Extended Data Fig. 4b). Since members of the AIF family were shown 
to possess NADH:ubiquinone oxidoreductase activity22, we hypothesized that FSP1 suppresses 
pLPO by regenerating lipophilic RTAs using NAD(P)H. The reduced form of coenzyme Q10 (CoQ10-
H2) was reported to be a good RTA in phospholipids and lipoproteins23, yet considered to be of 
limited value outside mitochondria because an efficient recycling mechanism is hitherto 
unknown. To investigate a possible link between FSP1 and CoQ10-H2, we generated CoQ10-
deficient HT1080 cells by deleting 4-hydroxybenzoate polyprenyltransferase (COQ2), the enzyme 
which catalyzing the first step in CoQ10 biosynthesis (Fig. 3c). CoQ10-deprived cells proliferated 
normally when supplemented with uridine, CoQ10 or decyl-ubiquinone (Extended Data Fig. 4c). 
Importantly, while FSP1 overexpression in parental HT1080 cells suppressed ferroptosis, it failed 
to do so in COQ2 KO cells (Fig. 3d; Extended Data Fig. 4d). Consistent with earlier data showing 
that purified FSP1 reduces ubiquinone analogs of variable chain lengths22, heterologously 
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expressed FSP1 (Extended Data Fig. 4e) catalyzed the reduction of a ubiquinone analog with an 
appended coumarin fluorophore. This enabled the determination of kinetic parameters for FSP1, 
which revealed a relatively low Km, and much higher Vmax compared to related oxidoreductases 
(e.g. NQO1), along with typically observed substrate inhibition (Fig. 3e). Importantly, neither 
dehydroascorbate, oxidized glutathione, nor tert-butyl hydroperoxide (TBOOH) were FSP1 
substrates (Fig. 3f).  
To further interrogate our hypothesis that FSP1 suppresses pLPO by reducing CoQ10, we carried 
out co-autoxidations of egg phosphatidylcholine and STY-BODIPY24 using a lipophilic alkoxyl 
radical generator (Extended Data Fig. 5a,b). Therein, neither FSP1 alone nor the combination of 
FSP1 and its reducing co-substrate, NAD(P)H, were able to suppress pLPO effectively (Extended 
Data Fig. 5c), while addition of CoQ10 retarded the autoxidation in a dose-dependent manner 
(Extended Data Fig. 5d,e). These results imply that, through FSP1, CoQ10 aids in importing the 
reducing equivalents from NAD(P)H into the lipid bilayer to inhibit propagation of lipid 
peroxidation. NQO1 was unable to serve in the same capacity as FSP1 in these assays (Extended 
Data Fig. 5f,g). Since CoQ10 is readily autoxidized and suffers from poor dynamics within the lipid 
bilayer25, we wondered if -tocopherol (-TOH) may also contribute to the protection observed 
by FSP1/CoQ10. Thus, following its reaction with a lipid-derived peroxyl radical, -TOH could be 
regenerated by reduced CoQ10, or even directly in vitro by FSP1 without the need for CoQ10 
(Extended Data Fig. 5h-j). Direct monitoring of phospholipid hydroperoxide formation in 
linoleate-rich liposomes corroborated the results of the co-autoxidations, showing substantial 
FSP1-catalyzed suppression of pLPO which was further enhanced in the presence of both CoQ10 
and -TOH (Extended Data Fig. 5k). 
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Loss of FSP1 sensitizes to ferroptosis 
Motivated by the strong protective effect provided by FSP1 and the possibility to maintain cells 
in the absence of GPX4, we envisioned that a counter-screen of FSP1 overexpressing cells in a 
GPX4 KO/WT background overexpressing FSP1 would be useful for the discovery of inhibitors of 
FSP1. We screened approximately 10,000 drug-like compounds4, which led to the identification 
of iFSP1 as a potent FSP1 inhibitor (Fig. 4a). iFSP1 selectively induced ferroptosis in GPX4 KO Pfa1 
and HT1080 cells overexpressing FSP1 (Extended Data Fig. 6a,b). Preliminary structure-activity 
relationship studies have yet to identify compounds with substantial improvement over iFSP1 
(Extended Data Fig. 6c). 
To determine if FSP1 could serve as a ferroptosis suppressor in cancer, we generated a 
monoclonal antibody against human FSP1 (Extended Data Fig. 6d), and explored its expression 
along with the main ferroptosis players in a panel of human cancer cell lines of different origins 
(Extended Data Fig. 7). Indeed, FSP1 was expressed in the majority of tumour cell lines, and iFSP1 
treatment robustly sensitized them to RSL3-induced ferroptosis (Extended Data Fig. 8). We then 
generated FSP1 KO and FSP1 overexpressing cells from a selection of these cell lines (Fig. 4b,c; 
Extended Data Fig. 7) and compared the effects of pharmacological inhibition (iFSP1) versus FSP1 
KO towards ferroptosis sensitisation. Expectedly, genetic FSP1 deletion was superior to small 
molecule inhibition, while iFSP1 treatment in the FSP1 KO background had no additive effect to 
RSL3 (Extended Data Fig. 6e,f). Notably, a few cells sensitive to RSL3 could not be re-sensitized 
by iFSP1 when FSP1 was overexpressed. This may be due to drug metabolization and excretion, 
and merit further investigation (Extended Data Fig. 6f). Detailed experiments demonstrated that 
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the FSP1 KO in MDA-MB-436 cells lowered their resistance to RSL3-induced ferroptosis, while 
mFSP1 re-expression restored ferroptosis resistance (Fig. 4d,e). Analysis of the cancer 
dependency map (DepMap - https://depmap.org/portal/) revealed that lower expression of FSP1 
correlates with an increased GPX4 dependency in a panel of 559 cancer cell lines (Extended Data 
Fig 9a). Additionally, FSP1 expression directly correlated with resistance to ferroptosis inducers 
RSL3, ML162 and ML210 in a panel of 860 cancer cell lines 
(https://portals.broadinstitute.org/ctrp) (Extended Data Fig. 9b). No synergistic cell death was 
detected with cisplatin or other known cytotoxic compounds (Extended Data Fig. 9c,d), 
suggesting that FSP1 inhibition selectively sensitizes cells to ferroptosis inducers. This finding is 
particularly important since therapy-resistant tumours only respond to complete elimination of 
GPX4 activity; minute amounts are sufficient to sustain cell viability26. Moreover, 
pharmacological targeting of GPX4 may only achieve partial anti-tumour effects. In fact, in mice 
bearing human xenografts, Besuker et al. demonstrate that the growth of H460 tumours can only 
be slowed by concomitant deletion of GPX4 and FSP1, whereas GPX4 single KO tumours grow 
normally. 
Our data unambiguously establish the NADH/FSP1/CoQ10 relay as a potent suppressor of pLPO 
and ferroptosis (Fig. 4f). As such, phospholipid redox homeostasis can be disassociated from the 
GSH/GPX4 axis, and can be further exploited pharmacologically to efficiently sensitize cancer cells 
to ferroptosis inducers. Our discovery explains why NAD(P)H27 and defects in the mevalonate 
pathway through loss of ubiquinone13,28 converge on FSP1 and thereby predict sensitivity to 
ferroptosis. Furthermore, our data provide a compelling case for the long-debated antioxidant 
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role of extra-mitochondrial CoQ1029,30 and advocates that its beneficial effects should be 
ultimately rationalized alongside FSP1. 
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Figure legends 
Figure 1 | Identification and validation of FSP1 as a robust ferroptosis suppressor. a, Scheme 
depicting the identification of AIFM2/FSP1 as a yet-unrecognized ferroptosis suppressor, using 
double-selection with 4-hydroxytamoxifen (TAM)-induced Gpx4 knockout (KO) followed by RSL3-
mediated elimination of false-positive cell clones. Surviving single cell clones were analysed by 
Sanger sequencing. b, Cell death induced by TAM was measured by lactate dehydrogenase (LDH) 
release of Pfa1 cells stably expressing Mock and FSP-HA using supernatants collected at the 
indicated time points in a 96-well plate. c-e, Dose-dependent toxicity of (1S, 3R)-RSL3 (RSL3)-
induced cell death of Pfa1 cells (WT or KO for GPX4) expressing Mock or FSP1-HA (c), HT1080 
cells expressing Mock or FSP1 (d), and HT1080 WT and HT1080 GPX4 KO cells overexpressing 
mock, hGPX4-FSH or FSP1-HA treated with and without 200 nM liproxstatin-1 (Lip-1)(e). Cell 
viability was assessed 24 h (b,c) or 72 h (d) thereafter using Aquabluer. Data represents the mean 
± s.d. of n = 3 wells of a 96-well plate from 1 representative of two (b), three (c-e) independent 
experiments, * P < 0.0001 (two-way ANOVA). 
 
Figure 2 | N-myristoylation of FSP1 is important for its anti-ferroptotic function. a, 
Immunobloting against ACSL4, FSP1, GPX4 and VCP of Pfa1 cells stably expressing Mock, FSP1-
HA or FSP1[G2A]-HA (left), parental HT1080 cells and HT1080 FSP1 KO cells stably Mock, FSP1 or 
FSP1[G2A] (right). Immunoblot pictures represent crop outs from the chemiluminescent signal 
files. For gel source data showing the overlap of colorimetric and chemiluminescent signals, see 
Supplementary Figure 1.  b, Specific enrichment of myristoylated proteins using metabolic 
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labeling with YnMyr myristate analogue followed by click chemistry to AzTB (Pfa1 FSP1-HA, Pfa1 
FSP1-HA + IMP-1088, Pfa1 FSP1[G2A]-HA, Pfa1 Mock). TAMRA in-gel fluorescence showing 
labelling of myristoylated proteins. FSP1 was specifically enriched with YnMyr and the 
enrichment was prevented by the pan-myristoylation inhibitor IMP-1088 as well as the 
FSP1[G2A] mutant, demonstrated by immunoblot analysis (HA antibody). Endogenously 
expressed ADP ribosylation factor like GTPase 1 (ARL1), served as positive control, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control. Immunoblot pictures 
represent crop outs from the chemiluminescent signal files. For gel source data showing the Cy5 
ladder and chemiluminescent signals separately, see Supplementary Figure 1. c, (left) Dose-
dependent toxicity of RSL3 in Pfa1 cells stably expressing Mock, FSP1-HA or FSP1[G2A]-HA. The 
FSP1[G2A] mutant failed to prevent RSL3-induced ferroptosis. (right) Inhibition of myristoylation 
(IMP-1088) in FSP1 overexpressing Gpx4 KO Pfa1 cells induced cell death in a dose-dependent 
manner, which was prevented by the ferroptosis inhibitor liproxstatin-1 (Lip-1). d, RSL3-induced 
cell death of HT1080 FSP1 KO cells stably expressing Mock, FSP1 or FSP1[G2A]. Cell viability was 
assessed after 24 h using Aquabluer (c,d). Data represents mean ± s.d. of n = 4 (c, left) or n = 3 
wells (c, right; d) of a 96-well plate from one representative of three (c,d) independent 
experiments, * P < 0.0001 (two-way ANOVA). e, Enhanced resolution confocal microscopy of 
HT1080 cells (FSP1-GFP or FSP1[G2A]-GFP) overexpressing mCherry-Sec61 beta (ER localization) 
or mApple-Golgi-7 (Golgi localization). GFP is displayed in green, while mCherry and mApple 
fluorescence are pseudo-colored in yellow. Scale bars indicate 10 µm and 2 µm in the overview 
and magnified images, respectively. 
 
 
17 
 
Figure 3 | FSP1 protects from unrestrained lipid peroxidation. a, Flow cytometry analysis of 
RSL3-induced (300 nM for 3 h) BODIPY 581/591 C11 oxidation in Pfa1 cells overexpressing Mock 
or FSP1-HA. Data shows one representative of two independently performed experiments. b, 
Heat map showing the representation of mono-oxidized phospholipid species (PE, 
phosphatidylethanolamines; PC, phosphatidylcholine) in Pfa1 Mock and Pfa1 FSP1-HA treated 
with or without 4-hydroxytamoxifen (TAM) for 48 h. For heatmap illustration, samples (n = 6) 
were averaged and normalized to cell number (1x106 cells). Each lipid species was normalized to 
its maximum level detected. Experiment was performed independently twice. Abbreviations (a, 
acyl; e, plasmanyl; p, plasmenyl/plasmalogen). c, LC/MS relative quantification of ubiquinone 
CoQ10 ([M+NH4]+ m/z: 880.7177, RT 22.8 min) in HT1080 parental and HT1080 COQ2-KO clones. 
Ubiquinone 9 ([M+NH4]+ m/z: 812.6551, RT 12.3 min) was used as internal standard. d, Dose-
dependent toxicity of RSL3 in HT1080 parental and COQ2-KO cells overexpressing FSP1-GFP, 
FSP1[G2A] or GFP. Cell viability was assessed after 24 h using Aquabluer. e, Kinetic parameters 
for the reduction of coumarin-quinone conjugate by FSP1 (50 nM, blue) and NQO1 (50 nM, red) 
in TBS (10 mM, pH 7.4) in the presence of NADH (200 µM) at 37°C. Initial rates were determined 
from the fluorescence of the product hydroquinone (ex = 415 nm, em = 470 nm). The data was 
fit to a standard substrate inhibition model and represent mean ± SD. f, NADH consumption assay 
(340 nm) in TBS buffer using recombinant purified hFSP1 in combination with different electron 
acceptor molecules (ubiquinone-1 (CoQ1), ubiquinone-10 (CoQ10), resazurin, oxidized glutathione 
(GSSG), dehydroascorbate, tert-butyl hydroperoxide (TBOOH)). Data shows n = 2 of one 
representative of three independent experiments (f). Data shows mean ± s.d. of n = 4 (d) or n = 
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3 (c,e) wells of a 96-well plate from one representative of three (e,f) or one (c,d) independent 
experiments, * P < 0.0001 one-way ANOVA (c) and two-way ANOVA (d). 
 
Figure 4 | FSP1 inhibition sensitizes tumor cells to ferroptosis. a, Chemical structure of iFSP1. 
Dose-dependent toxicity of iFSP1 of Pfa1 WT and GPX4 KO cells overexpressing FSP1-HA. b,c, 
Heatmaps depicting the dose-dependent toxicity of RSL3 in a panel of genetically engineered 
human cancer cell lines (FSP1 KO (b); FSP1 overexpressing, OE (c); for detailed cell viability assays 
including iFSP1 and liproxstatin-1 treatments please refer to Extended data Fig. 6e,f). d, 
Immunoblot analysis of FSP1, ACSL4, GPX4 and VCP of parental MDA-MB-436 cells and three 
independent FSP1 KO clones (KO #1-3) overexpressing Mock or murine FSP1 (mFSP1). 
Immunoblot pictures represent crop outs from the chemiluminescent signal files. For gel source 
data showing the overlap of colorimetric and chemiluminescent signals, see Supplementary 
Figure 1. e, Dose-dependent toxicity of RSL3 of the cell lines depicted in (d). Expression of FSP1 
restored resistance to RSL3-induced ferroptosis in all three clones. f, Graphical abstract depicting 
the anti-ferroptotic function of FSP1 as a glutathione-independent suppressor of phospholipid 
peroxidation by inhibition of lipid radical-mediated autoxidation (PLO·/OO·) of lipid bilayers. Data 
shows mean ± s.d. of n = 3 wells of a 96-well plate from one representative of one (a), two (b,c,e) 
independent experiments, * P < 0.01 (two-way ANOVA). 
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Extended Data Figure 1 | Identification and characterization of FSP1 as an anti-ferroptotic gene. 
a, Scheme depicting the generation of a lentiviral cDNA overexpression library using the total 
mRNA from MCF7 cells. b, Genomic PCRs of 14 (remaining clones after removal of false positives) 
Pfa1 cell clones using human specific primers amplifying the human cDNAs of GPX4 (571 bp) or 
AIFM2 (524 bp). The clones 2, 16, 24, 25, 26, 28 and 30 showed positive PCR results for GPX4 (571 
bp). Clones 1, 44, 45, 50, 51, 52 and 53 were positive for AIFM2 (524 bp) as indicated by the red 
arrows. Data shows one of n = 3 independent experiments. c, Immunoblot analysis of ACSL4, HA-
tag, GPX4 and ß-ACTIN of Pfa1 cells stably expressing Mock or FSP1-HA. Gpx4 deletion was 
induced via administration of 4-hydroxytamoxifen (TAM) for the indicated time. d, Immunoblot 
analysis of ACSL4, HA, GPX4 and ß-ACTIN of HT1080 (WT) and HT1080 GPX4 KO cells stably 
expressing Mock, GPX4-FSH or FSP1-HA. e, Proliferation of Pfa1 Mock and Pfa1 FSP1-HA cells 
treated with or without TAM. Cell numbers were assessed every 24 h using a Neubauer 
haemocytometer. Data shows mean ± s.d. of n = 3 wells of a 24-well plate from one 
representative of two independent experiments. f,g, Dose-dependent toxicity of Erastin and L-
buthionine sulfoximine (BSO) (g) induced cell death of Pfa1 cells expressing Mock or FSP1-HA. h,i, 
Dose-dependent toxicity of Erastin and L-buthionine sulfoximine (BSO), an inhibitor of -
glutamyl-cysteine ligase, (i) induced cell death of HT1080 cells expressing Mock or FSP1-HA. Cell 
viability was assessed 48 h (f,h) or 72 h (g,i) after treatments using Aquabluer. Data shows mean 
± s.d. of n = 3 wells of a 96-well plate from one representative of three (f-i) independent 
experiments, * P < 0.01 (two-way ANOVA). j, Measurement of total glutathione levels in Pfa1 
Mock, FSP1 and FSP1 GPX4 KO cells treated with or without BSO. Data shows mean ± s.d. of n = 
3 wells of a 96-well plate from one representative of three independent experiments. k, (left) 
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Determination of the NADPH consumption by glutathione reductase as an indirect measure of 
the GPX4 activity. Phosphatidylcholine lipid hydroperoxide (PCOOH) was used as a GPX4-specific 
substrate. Cell lysates from Pfa1 Mock and FSP1-HA cells treated with or without TAM for 48 h 
were used for the assay as shown by the immunoblot (FSP1, GPX4, ß-ACTIN) on the right. FSP1 
was detected using the polyclonal antibody (PA5-24562). Data shows mean ± s.d. of n = 3 wells 
of a 6-well plate from one representative of three independent experiments. Immunoblot 
pictures (c,d,k) represent crop outs from the chemiluminescent signal files. For gel source data 
(c,d,k) showing the overlap of colorimetric and chemiluminescent signals, see Supplementary 
Figure 1. 
Extended Data Figure 2 | FSP1 expression does not change the phospholipid composition. 
Lipidomic profile (only detectable phospholipid species of phosphatidylethanolamine PE, 
phosphatidylcholine PC, phosphatidylglycerol PG, phosphatidylinositol PI and phosphatidylserine 
PS including plasmenyl (O) and plasmanyl (P) lipids) of Pfa1 Mock, FSP1-HA and Gpx4 KO FSP1-
HA cells. Data represents the mean values of area of analyte (A)/internal standard (IS)/ total 
protein (mg) of n = 4 replicates of one experiment performed independently three times. log10 
has been applied to better visualize and compare the abundance of the different phospholipid 
species in the samples, * P < 0.05 (multiple t test with Sidak-Bonferroni correction for multiple 
comparisons). 
 
Extended Data Figure 3 | FSP1 is a highly specific anti-ferroptotic protein. a, Dose-dependent 
toxicity of phenylarsine oxide, indomethacin, auranofin, ivermectin, sunitinib, obatoclax, 
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mitoxantrone, irinotecan, vinblastine, ABT-263, nocodazole, etoposide, paclitaxel, H2O2 and tert-
butyl hydroperoxide (tBOOH) of Pfa1 cells expressing Mock or FSP1-HA. Cell viability was 
assessed 24 h after treatment using Aquabluer. b, Dose-dependent toxicity of TNF-α and 
staurosporine of Mock and FSP1-HA expressing Pfa1 cells. Cell viability was assessed 24 h after 
treatment using Aquabluer. c, Immunoblot analysis (ACSL4, HA, cleaved caspase 3 (clv. Casp3), 
GPX4 and ß-ACTIN) of Pfa1 FSP1-HA cells treated with or without TNF-α for 6 h. d, Immunoblot 
analysis of FSP1, ACSL4, P53, P21 and VCP of HT1080 p53 WT and KO (CRISPR CAS9 modified) cell 
lines treated with the MDM2 (MDM2 proto-oncogene) inhibitor Nutlin3 or the cytostatic 
compound doxorubicin (Doxo). Expression of FSP1 was not altered by Nutlin3 or Doxo treatment, 
while the expression of P53 and P21 was strongly induced in HT1080 P53 WT cells. Data shows 
one representative of n = 3 independent experiments. e, Flow cytometry analysis of annexin V/PI 
staining in Pfa1 cells expressing Mock or FSP1-HA treated with or without TNF-α for 4 h. No 
difference in the apoptotic activity was observed using the Alexa Fluor 488 /PE-Cy5 channels. 
Data shows one representative experiment of an experiment performed independently two 
times. f, Immunoblot analysis of AIFM1, ACSL4, GPX4 and ß-ACTIN in two different Pfa1 AIFM1 
KO cell clones overexpressing Mock or AIFM1. Data shows one representative of n = 3 
independent experiments. g, Dose-dependent toxicity of RSL3, Erastin and L-buthionine 
sulfoximine (BSO) of Pfa1 AIFM1 KO cell clones (#1 and #2) overexpressing Mock or AIFM1. AIFM1 
expression does not impact on ferroptosis sensitivity. Data shows the mean of n = 3 replicates of 
a representative experiment performed independently three times. h, Time-dependent lactate 
dehydrogenase (LDH) release of Pfa1 cells stably expressing Mock, FSP1-HA or FSP1[G2A] treated 
with TAM to induce GPX4 loss. Supernatants were collected from 6-well plates at different time 
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points after TAM induction and assayed for LDH content in a 96-well plate. i, HT1080 WT and 
HT1080 GPX4 KO cells overexpressing mock, hGPX4-FSH, FSP1-HA or FSP1[G2A]-HA treated with 
and without 200 nM Liproxstatin-1 (Lip-1). Cell viability was assessed after 72 h using Aquabluer. 
Data shows mean ± s.d. of n = 3 wells of a 96-well plate from one representative of three 
independent experiments (a, b, g, h, i), * P < 0.01 (two-way ANOVA). Immunoblot pictures (c,d,f) 
represent crop outs from the chemiluminescent signal files. For gel source data (c,d,f) showing 
the overlap of colorimetric and chemiluminescent signals, see Supplementary Figure 1. 
 
Extended Data Figure 4 | FSP1 protects from unrestrained lipid peroxidation in a Coq2 
dependent manner. a, Enhanced resolution confocal microscopy pictures demonstrating 
different localizations of FSP1-GFP and the FSP1[G2A]-GFP mutant in HT1080 cells. DAPI (yellow), 
GFP (green), ER-or Golgi-tracker (magenta) (Bars indicate 20 nm). Data shows one representative 
of n = 3 independently performed experiments. b, Formation of 5-H(P)ETE (MRM: 319 → 115), 
12-H(P)ETE (MRM: 319 → 179) and 15-H(P)ETE (MRM: 319 → 219) in either Mock (black) or FSP1-
HA overexpressing (red) Pfa1 cells treated with 0.2 µM RSL3 and 40 µM arachidonic acid. 
Hydroperoxides were analyzed as their alcohols following reduction with PPh3 
(triphenylphosphane) in methanol (Abbreviation: H(P)ETE, hydro(pero)xyeicosatetraenoic acid). 
Data shows the mean of biological triplicates from one representative of n = 3 independently 
performed experiments. c, Dose-dependent rescue of three independent HT1080 Coq2 KO cell 
clones (56, 61 and 68) by supplementation of the cell culture medium with uridine, CoQ10 or 
decyl-ubiquinone. Cell viability was assed using the Aquabluer assay 48 h after treatment. Data 
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shows mean ± s.d. of n = 3 wells of a 96-well plate performed once. d, Immunoblot analysis of 
FSP1 and ß-ACTIN in HT1080 parental (left) and HT1080 COQ2-KO (#56) (right) overexpressing 
FSP1-GFP, FSP1[G2A] or GFP. Immunoblot pictures represent crop outs from the 
chemiluminescent signal files. For gel source data showing the uncropped chemiluminescent 
signals, see Supplementary Figure 1. For gel source data, see Supplementary Figure 1. e, SDS gels 
showing the different purification steps of recombinant FSP1 from bacterial cell lysates. (left) SDS 
gel of protein extracts after initial nickel affinity chromatography (E1), the SUMO-tag was cleaved 
in the eluate by addition of the SUMO protease (dtUD1) and a second round of nickel affinity 
chromatography was performed to remove the cleaved SUMO-tag as well as uncleaved SUMO-
FSP1 and SUMO protease (E2). The flow through fraction was collected (2nd Ni). The SUMO-FSP1 
fusion protein is visible around 55kDa, and FSP1 at 40,5 kDa. (right) SDS gel showing different 
fractions containing FSP1 40,5 kDa (A8-A12, B1-B7 and C3-C4) from size exclusion 
chromatography of FSP1 after the second nickel affinity chromatography. Fractions C3 and C4 
were used for subsequent assays. One representative of at least three independent experiments.  
 
Extended Data Figure 5 | FSP1 protects from lipid peroxidation by reducing RTAs. a,b, Co-
autoxidations of STY-BODIPY (1 µM) (a) and the polyunsaturated lipids of (chicken) egg 
phosphatidylcholine liposomes (1 mM). The increase in fluorescence of ox-STY-BODIPY is 
monitored over the course of the autoxidation, which is initiated using C9-HN (0.2 mM) (b). c-j, 
Representative autoxidations inhibited by either 50 nM FSP1 (green), 8 µM NADH (purple), 16 
µM NADH (orange), 50 nM FSP1 and 8 µM NADH (black) or 50 nM FSP1 and 16 µM NADH (blue) 
(c). Analogous representative autoxidations inhibited to which CoQ10 (d, e), αTOH and CoQ10 (h, 
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i), or αTOH (j) were added. Recombinant NQO1 failed to suppress autoxidations in a similar way 
(f, g). k, 1-palmitoyl-2-linoleoyl-phosphatidylcholine hydroperoxide (PLPC-OOH) produced from 
the autoxidation of soy lecithin liposomes (13.3 mM), inhibited by FSP1 alone, or in the presence 
of either 10 µM CoQ10 or 10 µM αTOH and 10 µM CoQ10. PLPC-OOH was measured 0, 60, 120 and 
180 min after autoxidation was induced using LC-MS (MRM: 790 → 184). Data shows one of n = 
3 representative experiments. 
 
Extended Data Figure 6| Development of a FSP1-specific inhibitors (iFSP1) as ferroptosis 
sensitizer. a-b, Dose-dependent toxicity of iFSP1 (novel FSP1 inhibitor) in FSP1 overexpressing 
cells (Pfa1 (a); HT1080 (b)) with or without GPX4 loss. Treatment with the ferroptosis inhibitor 
liproxstatin-1 (Lip-1) (150 nM) protected GPX4 KO cells from iFSP1 induced ferroptosis. iFSP1 is 
only toxic to cells that depend solely (no GPX4 expression detectable) on FSP1 function. c, Efficacy 
of iFSP1 and structurally related analogues; EC50 values (mean ± s.d.) of iFSP1 (1) and its 
derivatives (2 - 14) calculated from experiments performed at least twice in triplicate are shown 
in the table with the corresponding chemical structures depicted below. Based on commercially 
available analogues a preliminary structure activity relationship (SAR) study revealed that 
substitution of the amino position (R1, R2) showed broad tolerability of aliphatic groups and that 
lipophilic substituents of the phenyl group at the 3-position (R3) in the ortho and meta positions 
were well tolerated. d, Immunoblot analysis of FSP1 and VCP in HT1080 parental as well as 
HT1080 FSP1 overexpressing and FSP1 KO cells. A self-made monoclonal antibody against human 
FSP1 was used. Immunoblot pictures represent crop outs from the chemiluminescent signal files. 
For gel source data showing the overlap of colorimetric and chemiluminescent signals, see 
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Supplementary Figure 1. e, Dose-dependent toxicity of RSL3 in a panel of genetically engineered 
(FSP1 KO) human cancer cell lines (NCl-H1437, NCl-H1437 FSP1 KO, U-373, U-373 FSP1 KO, MDA-
MB-436, MDA-MB-436 FSP1 KO, SW620, SW620 FSP1 KO, MDA-MB-435S, MDA-MB-435S 
FSP1KO, A549, A549 FSP1 KO) treated with or without FSP1 inhibitor (iFSP1) and liproxstatin-1 
(Lip-1). f, Dose-dependent toxicity of RSL3 in a panel of genetically modified (murine and human 
FSP1 overexpression) human cancer cell lines (IMR5/75 Mock, IMR5/75 hFSP1, 786-O Mock, 786-
O hFSP1, LOX-IMVI Mock, LOX-IMVI hFSP1, HLF Mock, HLF hFSP1, U-138 Mock, U-138 mFSP1) 
treated with or without iFSP-1 and Lip-1. Data shows the mean ± s.d. of n = 3 wells of a 96-well 
plate from one representative of three (a-c) or two (e, f) independent experiments, * P < 0.0001 
(two-way ANOVA). 
 
Extended Data Figure 7| FSP1 is expressed in a wide range of cancer cell lines. a, Immunoblot 
analysis of the expression of key ferroptosis players including ACSL4, FSP1, GPX4 and XCT 
(SLC7A11) in a panel of cancer cell lines from different origins. In addition, genetically modified 
cancer cell lines carrying a knockout of FSP1 (MDA-436-MB FSP1 KO, NCl-H1437 FSP1 KO, U-373 
FSP1 KO, MDA-MB-435S FSP1 KO, A549 FSP1 KO and SW620 FSP1 KO) as well as cell lines with 
lentiviral overexpression of FSP1 (IMR5/75 hFSP1, 786-O hFSP1, LOX-IMVI hFSP1 and HLF hFSP1) 
are shown. VCP (Valosin containing protein) or ß-ACTIN served as loading control. MDA-MB-231 
was used as reference to compare expression levels in between independent blots. Data shows 
one representative of two independent experiments. Immunoblot pictures represent crop outs 
from the chemiluminescent signal files. For gel source data showing the overlap of colorimetric 
and chemiluminescent signals, see Supplementary Figure 1.  
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Extended Data Figure 8| iFSP1 sensitized cancer cell lines from different origins to RSL3-induced 
ferroptosis. Dose-dependent toxicity of RSL3 in a panel of human cancer cell lines from different 
origins (breast, lung, pancreas, brain, liver, kidney, skin, intestine) treated with or without FSP1 
inhibitor (iFSP1) and liproxstatin-1 (Lip-1). Data shows the mean ± s.d. of n = 3 wells of a 96-well 
plate from one representative of two independent experiments. 
 
Extended Data Figure 9 | FSP1 expression directly correlated with resistance to ferroptosis and 
its inhibition selectively sensitizes cells to ferroptosis. a, Correlation of a panel of 860 cancer cell 
lines (https://portals.broadinstitute.org/ctrp) 31-33. The sensitivity to (1S,3R)-RSL3, ML162 and 
ML210 was correlated with gene expression. Genes were plotted according to their Pearson 
correlation score. FSP1 (AIFM2) was the highest ranking gene that correlated with resistance to 
(1S,3R)-RSL3 (P=0.392), ML162 (P=0.424) and ML210 (P=0.398). b, Dot plot depicting the 
correlation of a cell’s dependency on GPX4 (CERES score of -1 means full dependency based on 
CRISPR/Cas9 KO screen) and the expression level of FSP1 (AIFM2) in a panel of 559 different 
cancer cell lines (DepMap - https://depmap.org/portal/). DepMap publishes its data under CC 
Attribution 4.0 license. Cell lines with high expression of FSP1 were found to be less dependent 
on GPX4 (Pearson correlation score of 0.366, p-value= 3.38E-19). c, Dose-dependent toxicity of 
RSL3 in a panel of human lung cancer cells (NCl-H1437, NCl-H1299, NCl-H1573, NCl-H2126, NCl-
H520, NCl-H661) treated with or without the FSP1 inhibitor iFSP-1 (5 µM). Co-treatment of RSL3 
and iFSP-1 improved the ferroptotic response of all cell lines except NCl-H1437. d, Dose-
dependent toxicity of different cytotoxic compounds (Erastin, L-buthionine sulfoximine (BSO), 
RSL3, vinblastine, etoposide, phenylarsine oxide (PAO), mitoxantrone, irinotecan, nocodazole, 
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cisplatin) in Pfa1 Mock and FSP1 overexpressing cells treated with or without iFSP-1. The 
protective effect of FSP1 overexpression is lost upon iFSP-1 (5 µM) treatment. Data shows the 
mean ± s.d. of n = 3 wells of a 96-well plate from one representative of two independent 
experiments (c, d). 
 
